Duke Brain Tumor Immunotherapy Program,
Department of Neurosurgery,
Department of Biomedical Engineering,
Department of Pathology,
Duke Brain Tumor Immunotherapy Program, Department of Neurosurgery
John H. Sampson has not added Biography.
If you are John H. Sampson and would like to personalize this page please email our Author Liaison for assistance.
Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Seminars in immunology Oct, 2008 | Pubmed ID: 18539480
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma.
Neurosurgery Jan, 2002 | Pubmed ID: 11844246
Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Cancer immunology, immunotherapy : CII Feb, 2002 | Pubmed ID: 11862416
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar, 2002 | Pubmed ID: 11870184
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology May, 2002 | Pubmed ID: 11980998
Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.
Cancer research Jun, 2002 | Pubmed ID: 12067969
Intracanalicular meningioma mimicking vestibular schwannoma.
AJNR. American journal of neuroradiology Oct, 2002 | Pubmed ID: 12372737
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2002 | Pubmed ID: 12429640
Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Feb, 2003 | Pubmed ID: 12586801
Viruses in the treatment of brain tumors.
Neuroimaging clinics of North America Nov, 2002 | Pubmed ID: 12687911
Clinical immunotherapy for brain tumors.
Neuroimaging clinics of North America Nov, 2002 | Pubmed ID: 12687917
The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors.
Journal of neuro-oncology Aug-Sep, 2003 | Pubmed ID: 12952297
Adoptive immunotherapy for malignant glioma.
Cancer journal (Sudbury, Mass.) May-Jun, 2003 | Pubmed ID: 12952301
Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2003 | Pubmed ID: 14519652
Phase II trial of gefitinib in recurrent glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jan, 2004 | Pubmed ID: 14638850
Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.
Journal of neuro-oncology Oct, 2003 | Pubmed ID: 14649883
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2003 | Pubmed ID: 14654531
Immunotherapy of surgical malignancies.
Current problems in surgery Jan, 2004 | Pubmed ID: 14749625
Microvascular decompression for glossopharyngeal neuralgia: long-term effectiveness and complication avoidance.
Neurosurgery Apr, 2004 | Pubmed ID: 15046654
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2004 | Pubmed ID: 15131063
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Neuro-oncology Apr, 2004 | Pubmed ID: 15134628
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Neuro-oncology Apr, 2004 | Pubmed ID: 15134629
Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2004 | Pubmed ID: 15269159
Poliovirus receptor CD155-targeted oncolysis of glioma.
Neuro-oncology Jul, 2004 | Pubmed ID: 15279713
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.
Neuro-oncology Jan, 2005 | Pubmed ID: 15701286
Surgical management of petroclival meningiomas: defining resection goals based on risk of neurological morbidity and tumor recurrence rates in 137 patients.
Neurosurgery Mar, 2005 | Pubmed ID: 15730581
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Oct, 2005 | Pubmed ID: 16192602
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Dec, 2005 | Pubmed ID: 16361636
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2006 | Pubmed ID: 16467100
Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2006 | Pubmed ID: 16489093
Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.
Cancer research Mar, 2006 | Pubmed ID: 16540683
Convection-enhanced delivery of therapeutics for brain disease, and its optimization.
Neurosurgical focus , 2006 | Pubmed ID: 16709017
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
Neurosurgical focus , 2006 | Pubmed ID: 16709019
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Neurosurgical focus , 2006 | Pubmed ID: 16709020
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Jun, 2006 | Pubmed ID: 16741299
Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2006 | Pubmed ID: 16857805
Preoperative functional MR imaging localization of language and motor areas: effect on therapeutic decision making in patients with potentially resectable brain tumors.
Radiology Sep, 2006 | Pubmed ID: 16857981
Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.
Neurologia medico-chirurgica Oct, 2006 | Pubmed ID: 17062987
Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity.
Journal of neuroimmunology Jan, 2007 | Pubmed ID: 17137636
Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T cells in patients with malignant glioma reveals differential expression of the immunologic transcriptome compared with T cells from healthy volunteers.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2006 | Pubmed ID: 17189402
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
Journal of neuro-oncology May, 2007 | Pubmed ID: 17245623
Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning.
Neurosurgery Feb, 2007 | Pubmed ID: 17297371
Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
AJR. American journal of roentgenology Mar, 2007 | Pubmed ID: 17312057
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar, 2007 | Pubmed ID: 17327604
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function.
Clinical cancer research : an official journal of the American Association for Cancer Research Apr, 2007 | Pubmed ID: 17404100
Viruses in the treatment of malignant glioma.
Expert review of neurotherapeutics Apr, 2007 | Pubmed ID: 17425484
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions.
Neuro-oncology Jul, 2007 | Pubmed ID: 17435179
EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells.
Cancer immunology, immunotherapy : CII Jan, 2008 | Pubmed ID: 17634939
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.
Neuro-oncology Feb, 2008 | Pubmed ID: 17951512
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
Neuro-oncology Feb, 2008 | Pubmed ID: 18079360
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
Neurosurgery Nov, 2007 | Pubmed ID: 18091279
Cholesterol granuloma of the lateral ventricle. Case report.
Journal of neurosurgery Feb, 2008 | Pubmed ID: 18240934
Immunotherapy of malignant brain tumors.
Immunological reviews Apr, 2008 | Pubmed ID: 18363995
Cryptococcal meningitis in patients with glioma: a report of two cases.
Journal of neuro-oncology Aug, 2008 | Pubmed ID: 18398572
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.
Neuro-oncology Jun, 2008 | Pubmed ID: 18403491
Selective modification of antigen-specific T cells by RNA electroporation.
Human gene therapy May, 2008 | Pubmed ID: 18471037
Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma.
Expert review of anticancer therapy May, 2008 | Pubmed ID: 18471045
Combating immunosuppression in glioma.
Future oncology (London, England) Jun, 2008 | Pubmed ID: 18518768
Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Journal of immunological methods Nov, 2008 | Pubmed ID: 18775433
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2008 | Pubmed ID: 18794085
Stereotactic body radiotherapy for lesions of the spine and paraspinal regions.
International journal of radiation oncology, biology, physics Apr, 2009 | Pubmed ID: 19004569
Proteomic and immunologic analyses of brain tumor exosomes.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology May, 2009 | Pubmed ID: 19109410
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2009 | Pubmed ID: 19188181
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Mar, 2009 | Pubmed ID: 19204199
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.
Neuro-oncology Oct, 2009 | Pubmed ID: 19289491
Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma.
Cancer Jul, 2009 | Pubmed ID: 19402172
IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era.
International journal of cancer. Journal international du cancer Aug, 2009 | Pubmed ID: 19408307
Paraganglioma of the head and neck: long-term local control with radiotherapy.
American journal of clinical oncology Jun, 2009 | Pubmed ID: 19433962
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
Journal of neurochemistry May, 2009 | Pubmed ID: 19519779
Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Journal of neuro-oncology Dec, 2009 | Pubmed ID: 19533023
Toward effective immunotherapy for the treatment of malignant brain tumors.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics Jul, 2009 | Pubmed ID: 19560742
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Journal of neuro-oncology Jan, 2010 | Pubmed ID: 19562254
The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
Expert opinion on biological therapy Aug, 2009 | Pubmed ID: 19591631
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Nuclear medicine and biology Aug, 2009 | Pubmed ID: 19647172
EGFRvIII-targeted vaccination therapy of malignant glioma.
Brain pathology (Zurich, Switzerland) Oct, 2009 | Pubmed ID: 19744042
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Molecular cancer therapeutics Oct, 2009 | Pubmed ID: 19825799
Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.
Journal of neuro-oncology May, 2010 | Pubmed ID: 19898744
Clinical applications of a peptide-based vaccine for glioblastoma.
Neurosurgery clinics of North America Jan, 2010 | Pubmed ID: 19944970
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
Neurosurgery clinics of North America Jan, 2010 | Pubmed ID: 19944972
Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration.
Journal of neuro-oncology Jul, 2010 | Pubmed ID: 20020179
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Journal of neurosurgery Aug, 2010 | Pubmed ID: 20020841
Long-term safety of combined intracerebral delivery of free gadolinium and targeted chemotherapeutic agent PRX321.
Neurological research Oct, 2010 | Pubmed ID: 20021739
The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor.
Clinical neurosurgery , 2009 | Pubmed ID: 20214040
Immunotherapy approaches for malignant glioma from 2007 to 2009.
Current neurology and neuroscience reports Jul, 2010 | Pubmed ID: 20424975
Stereotactic radiosurgery in the treatment of a dural carotid-cavernous fistula.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society Jun, 2010 | Pubmed ID: 20431489
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Journal of neuro-oncology Jan, 2011 | Pubmed ID: 20443129
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
Journal of neuro-oncology Jan, 2011 | Pubmed ID: 20563833
Low-grade glioma.
Journal of neurosurgery Mar, 2011 | Pubmed ID: 20635855
A comprehensive outlook on intracerebral therapy of malignant gliomas.
Critical reviews in oncology/hematology Oct, 2011 | Pubmed ID: 20888252
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Nov, 2010 | Pubmed ID: 20921459
Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?
Neuro-oncology Jan, 2011 | Pubmed ID: 21149252
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Neuro-oncology Mar, 2011 | Pubmed ID: 21149254
Resection of vestibular schwannomas.
Journal of neurosurgery May, 2011 | Pubmed ID: 21250806
A novel method for volumetric MRI response assessment of enhancing brain tumors.
PloS one , 2011 | Pubmed ID: 21298088
Clinical trial end points for high-grade glioma: the evolving landscape.
Neuro-oncology Mar, 2011 | Pubmed ID: 21310734
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans.
Neurosurgery Sep, 2011 | Pubmed ID: 21430586
Bispecific antibodies engage T cells for antitumor immunotherapy.
Expert opinion on biological therapy Jul, 2011 | Pubmed ID: 21449821
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.
Journal of the National Comprehensive Cancer Network : JNCCN Apr, 2011 | Pubmed ID: 21464146
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
International journal of radiation oncology, biology, physics Apr, 2012 | Pubmed ID: 21489708
Epidemiology.
Journal of neurosurgery Aug, 2011 | Pubmed ID: 21529133
The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research Jun, 2011 | Pubmed ID: 21531816
Our failure to advance new treatments for glioma to market.
Journal of neurosurgery Aug, 2011 | Pubmed ID: 21568655
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Cancer Dec, 2011 | Pubmed ID: 21590689
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
Neurosurgery Jan, 2012 | Pubmed ID: 21593697
Convection-enhanced delivery.
Journal of neurosurgery Sep, 2011 | Pubmed ID: 21619413
Is cytomegalovirus a therapeutic target in glioblastoma?
Clinical cancer research : an official journal of the American Association for Cancer Research Jul, 2011 | Pubmed ID: 21632859
Disparities in care.
Journal of neurosurgery Feb, 2012 | Pubmed ID: 21740120
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans.
Blood Sep, 2011 | Pubmed ID: 21768296
Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Oct, 2011 | Pubmed ID: 21900098
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
Journal of neuro-oncology Jan, 2012 | Pubmed ID: 21938530
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Journal of neuro-oncology Mar, 2012 | Pubmed ID: 21986722
Avastin: more questions than answers. . .
Journal of neurosurgery Feb, 2012 | Pubmed ID: 22035270
Clinical data simplified.
Journal of neurosurgery Feb, 2012 | Pubmed ID: 22054209
Monitoring radiographic brain tumor progression.
Toxins Mar, 2011 | Pubmed ID: 22069705
Imaging of convection enhanced delivery of toxins in humans.
Toxins Mar, 2011 | Pubmed ID: 22069706
Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
Current drug discovery technologies Dec, 2012 | Pubmed ID: 22339070
Convection enhanced delivery of macromolecules for brain tumors.
Current drug discovery technologies Dec, 2012 | Pubmed ID: 22339074
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma.
PloS one , 2012 | Pubmed ID: 22383993
Toxin-based targeted therapy for malignant brain tumors.
Clinical & developmental immunology , 2012 | Pubmed ID: 22400035
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Journal of neuro-oncology Jul, 2012 | Pubmed ID: 22407177
Resection and survival.
Journal of neurosurgery Jun, 2012 | Pubmed ID: 22424561
The use of motor mapping to aid resection of eloquent gliomas.
Neurosurgery clinics of North America Apr, 2012 | Pubmed ID: 22440865
Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Journal of the National Comprehensive Cancer Network : JNCCN Jun, 2012 | Pubmed ID: 22679114
Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.
Cancer treatment reviews May, 2013 | Pubmed ID: 22727691
Editorial: Convection-enhanced delivery.
Journal of neurosurgery Dec, 2012 | Pubmed ID: 22998062
Enzyme redesign guided by cancer-derived IDH1 mutations.
Nature chemical biology Nov, 2012 | Pubmed ID: 23001033
Contemporary surgical management of vestibular schwannomas: analysis of complications and lessons learned over the past decade.
Neurosurgery Jun, 2013 | Pubmed ID: 23037828
Subarachnoid hemorrhage trials.
Journal of neurosurgery Jan, 2013 | Pubmed ID: 23039153
Regulatory T cells move in when gliomas say "I Do".
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2012 | Pubmed ID: 23052252
The limitations of imaging response criteria.
The Lancet. Oncology Nov, 2012 | Pubmed ID: 23116995
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.
Proceedings of the National Academy of Sciences of the United States of America Jan, 2013 | Pubmed ID: 23248284
Thickness of subcutaneous fat as a risk factor for infection in cervical spine fusion surgery.
The Journal of bone and joint surgery. American volume Feb, 2013 | Pubmed ID: 23426766
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.
PloS one , 2013 | Pubmed ID: 23527092
Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Journal of neurosurgery Jun, 2013 | Pubmed ID: 23581583
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide.
Cancer immunology, immunotherapy : CII Jun, 2013 | Pubmed ID: 23591978
Radiotherapy and radiosurgery for tumors of the central nervous system.
Surgical oncology clinics of North America Jul, 2013 | Pubmed ID: 23622073
Clinicopathological characteristics and treatment of rhabdoid glioblastoma.
Journal of neurosurgery Aug, 2013 | Pubmed ID: 23641829
Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
International journal of radiation oncology, biology, physics Aug, 2013 | Pubmed ID: 23725997
A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.
Oncoimmunology Apr, 2013 | Pubmed ID: 23734318
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.
Expert review of vaccines Jun, 2013 | Pubmed ID: 23750791
Complete response to steroids in dural inflammatory pseudotumor associated with Still's disease.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia Oct, 2013 | Pubmed ID: 23768965
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Journal of immunological methods Sep, 2013 | Pubmed ID: 23806556
Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.
Future oncology (London, England) Jul, 2013 | Pubmed ID: 23837761
An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.
Expert review of clinical pharmacology Jul, 2013 | Pubmed ID: 23927666
A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
Cancer immunology, immunotherapy : CII Nov, 2013 | Pubmed ID: 23982483
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia Jan, 2014 | Pubmed ID: 24054399
Enhanced oncolytic virotherapy through oxidative stress inhibition.
Molecular therapy : the journal of the American Society of Gene Therapy Nov, 2013 | Pubmed ID: 24201213
SEER insights.
Journal of neurosurgery Feb, 2014 | Pubmed ID: 24286150
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Clinical cancer research : an official journal of the American Association for Cancer Research Feb, 2014 | Pubmed ID: 24352643
Impact of PhD training on scholarship in a neurosurgical career.
Journal of neurosurgery Mar, 2014 | Pubmed ID: 24359004
Editorial on "heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial".
Neuro-oncology Jan, 2014 | Pubmed ID: 24443362
Methodology and reporting of meta-analyses in the neurosurgical literature.
Journal of neurosurgery Apr, 2014 | Pubmed ID: 24460491
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.
Oncoimmunology Dec, 2013 | Pubmed ID: 24475376
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.
Cancer immunology research Sep, 2013 | Pubmed ID: 24570975
Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2014 | Pubmed ID: 24658154
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma.
PloS one , 2014 | Pubmed ID: 24722266
Response.
Journal of neurosurgery Mar, 2014 | Pubmed ID: 24724172
Worse outcomes for patients undergoing brain tumor and cerebrovascular procedures following the ACGME resident duty-hour restrictions.
Journal of neurosurgery Aug, 2014 | Pubmed ID: 24926647
Oncolytic polio virotherapy of cancer.
Cancer Nov, 2014 | Pubmed ID: 24939611
A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastoma.
Journal of neurosurgery Sep, 2014 | Pubmed ID: 25036205
Immunological targeting of cytomegalovirus for glioblastoma therapy.
Oncoimmunology , 2014 | Pubmed ID: 25101224
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
Expert opinion on pharmacotherapy Oct, 2014 | Pubmed ID: 25139628
Antibody-based immunotherapy for malignant glioma.
Seminars in oncology Aug, 2014 | Pubmed ID: 25173142
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Immunotherapy Jun, 2014 | Pubmed ID: 25186601
Immunotherapy advances for glioblastoma.
Neuro-oncology Nov, 2014 | Pubmed ID: 25190673
Recurrent malignant gliomas.
Seminars in radiation oncology Oct, 2014 | Pubmed ID: 25219814
Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Expert opinion on biological therapy Jan, 2015 | Pubmed ID: 25327832
Epidermal growth factor receptor and variant III targeted immunotherapy.
Neuro-oncology Oct, 2014 | Pubmed ID: 25342601
Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.
The Journal of clinical investigation Dec, 2014 | Pubmed ID: 25347474
Severe Adverse Immunologic Reaction in a Patient with Glioblastoma Receiving Autologous Dendritic Cell Vaccines Combined with GM-CSF and Dose-Intensified Temozolomide.
Cancer immunology research Nov, 2014 | Pubmed ID: 25387895
Immunotherapy for primary brain tumors: no longer a matter of privilege.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2014 | Pubmed ID: 25398845
Defining the Optimal Planning Target Volume in Image-Guided Stereotactic Radiosurgery of Brain Metastases: Results of a Randomized Trial.
International journal of radiation oncology, biology, physics Oct, 2014 | Pubmed ID: 25442342
Peptide vaccines for the treatment of glioblastoma.
Journal of neuro-oncology Dec, 2014 | Pubmed ID: 25491947
Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma.
Cancer immunology, immunotherapy : CII Jan, 2015 | Pubmed ID: 25555571
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
Neuro-oncology Jan, 2015 | Pubmed ID: 25586468
Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: Implications for drug development.
Journal of neurochemistry Jan, 2015 | Pubmed ID: 25598002
Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy.
Oncoimmunology , 2014 | Pubmed ID: 25610727
Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.
Oncoimmunology , 2014 | Pubmed ID: 25610729
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。